Cargando…
Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region
BACKGROUND AND OBJECTIVES: Patients with diabetes mellitus inject insulin in different regions of the body. This study investigated the pharmacokinetic and pharmacodynamic properties of insulin degludec (IDeg), a new-generation once-daily basal insulin with an ultra-long duration of action, after su...
Autores principales: | Nosek, Leszek, Coester, Hans-Veit, Roepstorff, Carsten, Thomsen, Henrik F., Kristensen, Niels R., Haahr, Hanne, Heise, Tim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143594/ https://www.ncbi.nlm.nih.gov/pubmed/25124362 http://dx.doi.org/10.1007/s40261-014-0218-x |
Ejemplares similares
-
Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2014) -
Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions
por: Hövelmann, Ulrike, et al.
Publicado: (2017) -
Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes
por: Heise, Tim, et al.
Publicado: (2017) -
Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment
por: Kiss, István, et al.
Publicado: (2013) -
Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment
por: Kupčová, Viera, et al.
Publicado: (2013)